Bottom line
LHCTX vs VOO: the short answer
LHCTX (Lord Abbett Health Care Fund) and VOO (Vanguard 500 Index Fund) are both mutual funds.
But VOO is far broader, holding 520 positions to 61 for LHCTX, so beyond the top names it adds exposure LHCTX doesn't have.
VOO is cheaper at 0.03% vs 0.78% — a difference of $75 a year per $10,000 invested.
Over five years, VOO returned +14.4% a year vs +4.6% for LHCTX.
Updated Nov 19, 2026
LHCTX vs VOO side by side
| LHCTX | VOO | |
|---|---|---|
| Type | Mutual fund | ETF |
| Fund family | Lord Abbett | Vanguard |
| Category | Health Care Sector | S&P 500 Index |
| Expense ratio | 0.78% | 0.03% |
| Annual cost per $10k | $78 | $3 |
| 10-yr cost on $10k (prospectus) | $3,362 | $39 |
| Max front load | 0% | None |
| 12b-1 fee | 0% | 0% |
| 1-yr return | +18.0% | +17.8% |
| 5-yr return (annualized) | +4.6% | +14.4% |
| 10-yr return (annualized) | — | +14.8% |
| Best quarter | — | +20.5% |
| Worst quarter | — | −19.6% |
| Net assets (fund) | $8.6M | $1.7T |
| Number of holdings | 61 | 520 |
| Portfolio turnover | 91% | 2% |
| Returns as of | Dec 31, 2025 | Dec 31, 2025 |
Source: SEC Form N-PORT and fund prospectuses
Holdings overlap
2 of LHCTX's top 25 holdings also appear in VOO's top 25.
| Holding | LHCTX | VOO |
|---|---|---|
| Eli Lilly & Co | 10.40% | 1.47% |
| Johnson & Johnson | 4.96% | 0.95% |
Source: SEC Form N-PORT
LHCTX top 10
- Eli Lilly & Co — 10.40%
- UnitedHealth Group Inc — 5.39%
- Johnson & Johnson — 4.96%
- Novartis AG — 4.19%
- Natera Inc — 3.60%
- Gilead Sciences Inc — 3.53%
- CVS Health Corp — 3.33%
- Guardant Health Inc — 2.61%
- Galderma Group AG — 2.60%
- Thermo Fisher Scientific Inc — 2.31%
VOO top 10
- NVIDIA Corp — 7.51%
- Apple Inc — 6.59%
- Microsoft Corp — 4.30%
- Amazon.com Inc — 3.62%
- Alphabet Inc — 3.25%
- Broadcom Inc — 2.77%
- Alphabet Inc — 2.59%
- Micron Technology Inc — 2.02%
- Meta Platforms Inc — 1.92%
- Tesla Inc — 1.84%
FAQ
What is the difference between LHCTX and VOO?
Which is cheaper, LHCTX or VOO?
Should I own both LHCTX and VOO?
Educational comparison based on public filings; not investment advice. Past performance does not guarantee future results.